Sign In
Buy ICCM
$0.152
+0.0127 (+9.14%)
At Close: Jun 03, 2026
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
08:30am, Wednesday, 20'th Nov 2024
CAESAREA, Israel , Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and bre
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
07:00am, Friday, 08'th Nov 2024
FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel , Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "
Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA website FDA Advisory Panel providing recommendations and vote on information co
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
08:30am, Monday, 21'st Oct 2024
Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel , Oct. 21, 2024 /PRNewswire/ --
ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cry
Bet on 5 Top-Ranked Stocks With Rising P/E
05:30am, Wednesday, 02'nd Oct 2024
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Adverum Biotechnologies (ADVM), IceCure Medical (ICCM), DarioHealth (DRIO), Energous (WATT) and V
Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7, 2024 96.3% recurrence free rate for
Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage Independent study conduct
Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer F DA
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
08:30am, Wednesday, 04'th Sep 2024
Company presentation to focus on how IceCure's industry-leading ProSense® enables non-surgical treatment of benign and cancerous tumors and upcoming n ear-term regulatory and operating catalysts
Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fields Over 50 patents issued and allowed worldwide for IceCure's platform cryoablatio
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates
10:41am, Tuesday, 20'th Aug 2024
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07.
Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Easte
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
08:30am, Wednesday, 14'th Aug 2024
After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100% Study concluded that most non-surgical patients with early-stage breast can
